Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
about
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsComparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.Ceftaroline fosamil: drug profile and clinical data.Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infectionCeftaroline: a cephalosporin with expanded Gram-positive activity.In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceIn vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI).Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolatesResponse of a clinical Escherichia coli strain to repeated cefquinome exposure in a piglet tissue-cage model.Ceftaroline in complicated skin and skin-structure infections.Pharmacokinetics of ceftaroline in normal body weight and obese (classes I, II, and III) healthy adult subjectsClinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumoniaProbability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolatesReduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from AustraliaEfficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes.Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjectsInvestigational treatments for postoperative surgical site infections.Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Monte Carlo simulations based on phase 1 studies predict target attainment of ceftobiprole in nosocomial pneumonia patients: a validation studyIn vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection modelsOritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.PK/PD models in antibacterial development.Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.Ceftobiprole: a new broad spectrum cephalosporin.Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.Ceftaroline for complicated skin and skin-structure infections.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Ceftaroline fosamil: a new broad-spectrum cephalosporin.Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
P2860
Q24672937-8F766E0B-3931-4C9B-AB86-1E4BCCBC7609Q33613654-7949F8D0-77E1-485B-9A20-BCD15CC961BFQ33772804-2AAACCC6-4078-43D5-B6A7-9B23B36B63CBQ33797936-7917212A-7242-4B14-AC0F-2C5CF54BB09DQ34016030-4628AD85-2C54-4D7D-AE39-BF6B9443D8AEQ34299028-3DACD642-BDDD-4F3D-A89B-7FE6A0EF53CBQ34309420-4F2DD55B-4346-4EBD-A2C3-CEB67C944D7DQ34726196-A7EFA464-2A9A-44DA-A490-DC13C05BA888Q34922533-72702E19-02C5-45CF-AE72-BC0A7261BC4EQ35065778-A19D9ED8-1C64-4280-B598-B3BB462C6D4AQ35065798-0E438023-6057-46FE-8EED-3DB5F79A57D6Q35105932-4389DC90-D435-4C62-911C-5E34C3D598F7Q35117981-65245285-C455-4369-979B-E84DE51D501FQ35191501-79DB9E95-F412-478C-B5C2-2E7A43D8C1DEQ35712872-2F703FC7-259A-47F6-AED6-BBC601E10B3CQ35715381-F2FEA28B-EA49-4989-AF30-8A155BBC42D5Q35746176-FAFF7977-6AC3-4A2F-9375-7DF67592F034Q35752997-283AC717-DFC5-4463-BEDE-CF1968AB46CEQ35879080-0B94C550-E0CA-4727-B4B9-C3FD2EF918C4Q35941308-2979D9DD-DFDA-4611-9260-B3B083B1B4B1Q36290502-E61B5ABD-C08F-4D2B-BBFF-6DEBF080CBB5Q36396172-56ADF4E3-7116-4B54-9823-18177DF4352CQ36571798-B22036B3-D9E0-4DCA-933E-99E00A3EF570Q36667104-AA5E74B1-2044-4E9F-8C0F-E7DCA34032DEQ36715742-B8ECC21D-603A-4E27-BE74-8F4DB71C3EF0Q36763997-7F343901-0277-4CDA-B889-D8015FFC416CQ36785934-25522E09-47DC-4EC1-BAE4-BF229DC48E14Q36932924-20B39F2B-74A9-45CA-9FAD-8D507751CDE7Q37071199-E6F20072-A953-4A06-A77B-BCE13722E96AQ37287884-28B21056-30D6-4A79-9E75-EE8CA9F1CE2CQ37325658-F9BE7239-BCB0-4F53-819E-3A22F232B969Q37335859-CA7AC839-754A-4DCE-B40F-0DE1E11FB120Q37519733-D20B2DF3-10D8-4CC5-B65E-2E560B91A63CQ37713040-CD42E0DC-FDEA-4FFE-B8B6-F046D950D670Q37718228-6AC9E90E-B6D2-4DAD-ADE9-A60F10879122Q37733561-81BA3C83-3BBA-4B30-8958-7C1769F8B039Q37800939-895E440A-23C6-4433-BDCA-12FB6829BB15Q37863942-3B4FDE1C-E2E7-4C47-BB2B-044C2BAB7103Q37947221-B373B82F-3164-43C9-99F0-5574A307A278Q38010783-D22128AC-6199-41E1-BD4A-4276D5655775
P2860
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@ast
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@en
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@nl
type
label
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@ast
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@en
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@nl
prefLabel
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@ast
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@en
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@nl
P2860
P1476
Pharmacodynamics of a new ceph ...... inetic-pharmacodynamic target.
@en
P2093
P2860
P304
P356
10.1128/AAC.50.4.1376-1383.2006
P407
P577
2006-04-01T00:00:00Z